ID   AKT3_HUMAN              Reviewed;         479 AA.
AC   Q9Y243; Q0VAA6; Q5VTI1; Q5VTI2; Q96QV3; Q9UFP5;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   10-MAY-2017, entry version 184.
DE   RecName: Full=RAC-gamma serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase Akt-3;
DE   AltName: Full=Protein kinase B gamma;
DE            Short=PKB gamma;
DE   AltName: Full=RAC-PK-gamma;
DE   AltName: Full=STK-2;
GN   Name=AKT3; Synonyms=PKBG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS.
RX   PubMed=10092583; DOI=10.1074/jbc.274.14.9133;
RA   Brodbeck D., Cron P., Hemmings B.A.;
RT   "A human protein kinase B gamma with regulatory phosphorylation sites
RT   in the activation loop and in the C-terminal hydrophobic domain.";
RL   J. Biol. Chem. 274:9133-9136(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10208883; DOI=10.1006/bbrc.1999.0559;
RA   Nakatani K., Sakaue H., Thompson D.A., Weigel R.J., Roth R.A.;
RT   "Identification of a human Akt3 (protein kinase B gamma) which
RT   contains the regulatory serine phosphorylation site.";
RL   Biochem. Biophys. Res. Commun. 257:906-910(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=10491192; DOI=10.1046/j.1432-1327.1999.00774.x;
RA   Masure S., Haefner B., Wesselink J.-J., Hoefnagel E., Mortier E.,
RA   Verhasselt P., Tuytelaars A., Gordon R., Richardson A.;
RT   "Molecular cloning, expression and characterization of the human
RT   serine/threonine kinase Akt-3.";
RL   Eur. J. Biochem. 265:353-360(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Li X., Yu L., Huang H., Zhang M., Zhao Y., Zhao S.;
RT   "Cloning of a novel human cDNA, STK-2, which encodes a rat serine-
RT   threonine protein kinase (STK) homolog.";
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND MUTAGENESIS OF
RP   THR-305 AND THR-447.
RX   PubMed=11387345; DOI=10.1074/jbc.M104633200;
RA   Brodbeck D., Hill M.M., Hemmings B.A.;
RT   "Two splice variants of PKB gamma have different regulatory capacity
RT   depending on the presence or absence of the regulatory phosphorylation
RT   site Ser-472 in the C-terminal hydrophobic domain.";
RL   J. Biol. Chem. 276:29550-29558(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   CHARACTERIZATION, AND PHOSPHORYLATION AT THR-305 BY PDPK1.
RX   PubMed=9512493; DOI=10.1042/bj3310299;
RA   Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.;
RT   "Activation of protein kinase B beta and gamma isoforms by insulin in
RT   vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro:
RT   comparison with protein kinase B alpha.";
RL   Biochem. J. 331:299-308(1998).
RN   [11]
RP   PHOSPHORYLATION AT SER-472.
RX   PubMed=12162751; DOI=10.1021/bi026065r;
RA   Hodgkinson C.P., Sale E.M., Sale G.J.;
RT   "Characterization of PDK2 activity against protein kinase B gamma.";
RL   Biochemistry 41:10351-10359(2002).
RN   [12]
RP   INTERACTION WITH TCL1A.
RX   PubMed=11707444; DOI=10.1074/jbc.M107069200;
RA   Laine J., Kuenstle G., Obata T., Noguchi M.;
RT   "Differential regulation of Akt kinase isoforms by the members of the
RT   TCL1 oncogene family.";
RL   J. Biol. Chem. 277:3743-3751(2002).
RN   [13]
RP   INTERACTION WITH TCL1A.
RX   PubMed=11839817; DOI=10.1128/MCB.22.5.1513-1525.2002;
RA   Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F.,
RA   Roumestand C., Stern M.H., Noguchi M.;
RT   "Identification of Akt association and oligomerization domains of the
RT   Akt kinase coactivator TCL1.";
RL   Mol. Cell. Biol. 22:1513-1525(2002).
RN   [14]
RP   INVOLVEMENT IN TUMORS.
RX   PubMed=15466193; DOI=10.1158/0008-5472.CAN-04-1399;
RA   Stahl J.M., Sharma A., Cheung M., Zimmerman M., Cheng J.Q.,
RA   Bosenberg M.W., Kester M., Sandirasegarane L., Robertson G.P.;
RT   "Deregulated Akt3 activity promotes development of malignant
RT   melanoma.";
RL   Cancer Res. 64:7002-7010(2004).
RN   [15]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=17178867; DOI=10.1158/0008-5472.CAN-06-1968;
RA   Cristiano B.E., Chan J.C., Hannan K.M., Lundie N.A., Marmy-Conus N.J.,
RA   Campbell I.G., Phillips W.A., Robbie M., Hannan R.D., Pearson R.B.;
RT   "A specific role for AKT3 in the genesis of ovarian cancer through
RT   modulation of G(2)-M phase transition.";
RL   Cancer Res. 66:11718-11725(2006).
RN   [16]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16540465; DOI=10.1074/jbc.M601384200;
RA   Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A.,
RA   Kendall R.L.;
RT   "Kinetic mechanism of AKT/PKB enzyme family.";
RL   J. Biol. Chem. 281:13949-13956(2006).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [18]
RP   FUNCTION.
RX   PubMed=18524868; DOI=10.1096/fj.08-106468;
RA   Wright G.L., Maroulakou I.G., Eldridge J., Liby T.L., Sridharan V.,
RA   Tsichlis P.N., Muise-Helmericks R.C.;
RT   "VEGF stimulation of mitochondrial biogenesis: requirement of AKT3
RT   kinase.";
RL   FASEB J. 22:3264-3275(2008).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   UBIQUITINATION BY TTC3.
RX   PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007;
RA   Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J.,
RA   Hirata N., Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C.,
RA   Hatakeyama S., Obata T., Noguchi M.;
RT   "The E3 ligase TTC3 facilitates ubiquitination and degradation of
RT   phosphorylated Akt.";
RL   Dev. Cell 17:800-810(2009).
RN   [21]
RP   INTERACTION WITH TRAF6.
RX   PubMed=19713527; DOI=10.1126/science.1175065;
RA   Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B.,
RA   Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.;
RT   "The E3 ligase TRAF6 regulates Akt ubiquitination and activation.";
RL   Science 325:1134-1138(2009).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20018949; DOI=10.1152/ajpcell.00375.2009;
RA   Santi S.A., Lee H.;
RT   "The Akt isoforms are present at distinct subcellular locations.";
RL   Am. J. Physiol. 298:C580-C591(2010).
RN   [23]
RP   INVOLVEMENT IN TUMORS.
RX   PubMed=20167810; DOI=10.1093/neuonc/nop026;
RA   Mure H., Matsuzaki K., Kitazato K.T., Mizobuchi Y., Kuwayama K.,
RA   Kageji T., Nagahiro S.;
RT   "Akt2 and Akt3 play a pivotal role in malignant gliomas.";
RL   Neuro-oncol. 12:221-232(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   FUNCTION.
RX   PubMed=21191416; DOI=10.1038/jid.2010.361;
RA   Moriya C., Jinnin M., Yamane K., Maruo K., Muchemwa F.C., Igata T.,
RA   Makino T., Fukushima S., Ihn H.;
RT   "Expression of matrix metalloproteinase-13 is controlled by IL-13 via
RT   PI3K/Akt3 and PKC-delta in normal human dermal fibroblasts.";
RL   J. Invest. Dermatol. 131:655-661(2011).
RN   [26]
RP   REVIEW ON FUNCTION.
RX   PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004;
RA   Hers I., Vincent E.E., Tavare J.M.;
RT   "Akt signalling in health and disease.";
RL   Cell. Signal. 23:1515-1527(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-447, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.46 ANGSTROMS) OF 1-118.
RA   Vollmar M., Wang J., Zhang Y., Elkins J.M., Burgess-Brown N.,
RA   Chaikuad A., Pike A.C.W., Von Delft F., Bountra C., Arrowsmith C.H.,
RA   Weigelt J., Edwards A., Knapp S.;
RT   "The crystal structure of the PH domain of human Akt3 protein
RT   kinase.";
RL   Submitted (DEC-2009) to the PDB data bank.
RN   [29]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-171.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [30]
RP   VARIANT MELANOMA LYS-17, AND CHARACTERIZATION OF VARIANT MELANOMA
RP   LYS-17.
RX   PubMed=18813315; DOI=10.1038/sj.bjc.6604637;
RA   Davies M.A., Stemke-Hale K., Tellez C., Calderone T.L., Deng W.,
RA   Prieto V.G., Lazar A.J., Gershenwald J.E., Mills G.B.;
RT   "A novel AKT3 mutation in melanoma tumours and cell lines.";
RL   Br. J. Cancer 99:1265-1268(2008).
RN   [31]
RP   VARIANTS MPPH2 SER-229 AND TRP-465.
RX   PubMed=22729224; DOI=10.1038/ng.2331;
RA   Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D.,
RA   Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W.,
RA   Nikkel S.M., Worthylake T., Sullivan C.T., Ward T.R., Butler H.E.,
RA   Kramer N.A., Albrecht B., Armour C.M., Armstrong L., Caluseriu O.,
RA   Cytrynbaum C., Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E.,
RA   Mancini G.M., Meschino W.S., Reggin J.D., Saggar A.K.,
RA   Lerman-Sagie T., Uyanik G., Weksberg R., Zirn B., Beaulieu C.L.,
RA   Majewski J., Bulman D.E., O'Driscoll M., Shendure J., Graham J.M. Jr.,
RA   Boycott K.M., Dobyns W.B.;
RT   "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA
RT   cause a spectrum of related megalencephaly syndromes.";
RL   Nat. Genet. 44:934-940(2012).
RN   [32]
RP   VARIANT MPPH2 LYS-17.
RX   PubMed=22729223; DOI=10.1038/ng.2329;
RA   Lee J.H., Huynh M., Silhavy J.L., Kim S., Dixon-Salazar T.,
RA   Heiberg A., Scott E., Bafna V., Hill K.J., Collazo A., Funari V.,
RA   Russ C., Gabriel S.B., Mathern G.W., Gleeson J.G.;
RT   "De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway
RT   cause hemimegalencephaly.";
RL   Nat. Genet. 44:941-945(2012).
RN   [33]
RP   VARIANT MPPH2 LYS-17.
RX   PubMed=22500628; DOI=10.1016/j.neuron.2012.03.010;
RA   Poduri A., Evrony G.D., Cai X., Elhosary P.C., Beroukhim R.,
RA   Lehtinen M.K., Hills L.B., Heinzen E.L., Hill A., Hill R.S.,
RA   Barry B.J., Bourgeois B.F., Riviello J.J., Barkovich A.J., Black P.M.,
RA   Ligon K.L., Walsh C.A.;
RT   "Somatic activation of AKT3 causes hemispheric developmental brain
RT   malformations.";
RL   Neuron 74:41-48(2012).
RN   [34]
RP   VARIANT MPPH2 SER-229.
RX   PubMed=23745724; DOI=10.1111/cge.12188;
RA   Nakamura K., Kato M., Tohyama J., Shiohama T., Hayasaka K.,
RA   Nishiyama K., Kodera H., Nakashima M., Tsurusaki Y., Miyake N.,
RA   Matsumoto N., Saitsu H.;
RT   "AKT3 and PIK3R2 mutations in two patients with megalencephaly-related
RT   syndromes: MCAP and MPPH.";
RL   Clin. Genet. 85:396-398(2014).
CC   -!- FUNCTION: AKT3 is one of 3 closely related serine/threonine-
CC       protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and
CC       which regulate many processes including metabolism, proliferation,
CC       cell survival, growth and angiogenesis. This is mediated through
CC       serine and/or threonine phosphorylation of a range of downstream
CC       substrates. Over 100 substrate candidates have been reported so
CC       far, but for most of them, no isoform specificity has been
CC       reported. AKT3 is the least studied AKT isoform. It plays an
CC       important role in brain development and is crucial for the
CC       viability of malignant glioma cells. AKT3 isoform may also be the
CC       key molecule in up-regulation and down-regulation of MMP13 via
CC       IL13. Required for the coordination of mitochondrial biogenesis
CC       with growth factor-induced increases in cellular energy demands.
CC       Down-regulation by RNA interference reduces the expression of the
CC       phosphorylated form of BAD, resulting in the induction of caspase-
CC       dependent apoptosis. {ECO:0000269|PubMed:18524868,
CC       ECO:0000269|PubMed:21191416}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Two specific sites, one in the kinase domain
CC       (Thr-305) and the other in the C-terminal regulatory region (Ser-
CC       472), need to be phosphorylated for its full activation (By
CC       similarity). IGF-1 leads to the activation of AKT3, which may play
CC       a role in regulating cell survival. {ECO:0000250}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=87.9 uM for ATP (for purified and in vitro activated AKT3)
CC         {ECO:0000269|PubMed:16540465};
CC         KM=12.4 uM for peptide substrate (for purified and in vitro
CC         activated AKT3) {ECO:0000269|PubMed:16540465};
CC         KM=118.7 uM for ATP (for recombinant myristoylated AKT3
CC         expressed and immunoprecipitated from Rat-1 cells)
CC         {ECO:0000269|PubMed:16540465};
CC         KM=2.3 uM for peptide substrate (for recombinant myristoylated
CC         AKT3 expressed and immunoprecipitated from Rat-1 cells)
CC         {ECO:0000269|PubMed:16540465};
CC   -!- SUBUNIT: Interacts (via PH domain) with TCL1A; this enhances AKT3
CC       phosphorylation and activation. Interacts with TRAF6. Interacts
CC       with KCTD20 (By similarity). Interacts with BTBD10 (By
CC       similarity). {ECO:0000250|UniProtKB:Q9WUA6,
CC       ECO:0000269|PubMed:11707444, ECO:0000269|PubMed:11839817,
CC       ECO:0000269|PubMed:19713527}.
CC   -!- INTERACTION:
CC       P42574:CASP3; NbExp=2; IntAct=EBI-296115, EBI-524064;
CC       Q16543:CDC37; NbExp=2; IntAct=EBI-296115, EBI-295634;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20018949}.
CC       Cytoplasm {ECO:0000269|PubMed:20018949}. Membrane
CC       {ECO:0000269|PubMed:20018949}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:20018949}. Note=Membrane-associated after cell
CC       stimulation leading to its translocation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=PKB gamma;
CC         IsoId=Q9Y243-1; Sequence=Displayed;
CC       Name=2; Synonyms=PKB gamma 1;
CC         IsoId=Q9Y243-2; Sequence=VSP_004947;
CC   -!- TISSUE SPECIFICITY: In adult tissues, it is highly expressed in
CC       brain, lung and kidney, but weakly in heart, testis and liver. In
CC       fetal tissues, it is highly expressed in heart, liver and brain
CC       and not at all in kidney.
CC   -!- DOMAIN: Binding of the PH domain to the phosphatidylinositol 3-
CC       kinase alpha (PI(3)K) results in its targeting to the plasma
CC       membrane.
CC   -!- PTM: Phosphorylation on Thr-305 and Ser-472 is required for full
CC       activity. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. When fully phosphorylated and translocated
CC       into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed
CC       by TTC3, leading to its degradation by the proteasome.
CC       {ECO:0000269|PubMed:12162751, ECO:0000269|PubMed:20059950,
CC       ECO:0000269|PubMed:9512493}.
CC   -!- PTM: O-GlcNAcylation at Thr-302 and Thr-309 inhibits activating
CC       phosphorylation at Thr-305 via disrupting the interaction between
CC       AKT and PDK1. {ECO:0000250}.
CC   -!- DISEASE: Note=AKT3 is a key modulator of several tumors like
CC       melanoma, glioma and ovarian cancer. Active AKT3 increases
CC       progressively during melanoma tumor progression with highest
CC       levels present in advanced-stage metastatic melanomas. Promotes
CC       melanoma tumorigenesis by decreasing apoptosis. Plays a key role
CC       in the genesis of ovarian cancers through modulation of G2/M phase
CC       transition. With AKT2, plays a pivotal role in the biology of
CC       glioblastoma.
CC   -!- DISEASE: Megalencephaly-polymicrogyria-polydactyly-hydrocephalus
CC       syndrome 2 (MPPH2) [MIM:615937]: A syndrome characterized by
CC       megalencephaly, hydrocephalus, and polymicrogyria; polydactyly may
CC       also be seen. There is considerable phenotypic similarity between
CC       this disorder and the megalencephaly-capillary malformation
CC       syndrome. {ECO:0000269|PubMed:22500628,
CC       ECO:0000269|PubMed:22729223, ECO:0000269|PubMed:22729224,
CC       ECO:0000269|PubMed:23745724}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. RAC subfamily. {ECO:0000305}.
CC   -!- CAUTION: In light of strong homologies in the primary amino acid
CC       sequence, the 3 AKT kinases were long surmised to play redundant
CC       and overlapping roles. More recent studies has brought into
CC       question the redundancy within AKT kinase isoforms and instead
CC       pointed to isoform specific functions in different cellular events
CC       and diseases. AKT1 is more specifically involved in cellular
CC       survival pathways, by inhibiting apoptotic processes; whereas AKT2
CC       is more specific for the insulin receptor signaling pathway.
CC       Moreover, while AKT1 and AKT2 are often implicated in many aspects
CC       of cellular transformation, the 2 isoforms act in a complementary
CC       opposing manner. The role of AKT3 is less clear, though it appears
CC       to be predominantly expressed in brain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AKT3ID615ch1q44.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF124141; AAD29089.1; -; mRNA.
DR   EMBL; AF135794; AAD24196.1; -; mRNA.
DR   EMBL; AF085234; AAL40392.1; -; mRNA.
DR   EMBL; AJ245709; CAB53537.1; -; mRNA.
DR   EMBL; AL117525; CAB55977.1; ALT_TERM; mRNA.
DR   EMBL; AY005799; AAF91073.1; -; mRNA.
DR   EMBL; AL591721; CAH71866.1; -; Genomic_DNA.
DR   EMBL; AC096539; CAH71866.1; JOINED; Genomic_DNA.
DR   EMBL; AL592151; CAH71866.1; JOINED; Genomic_DNA.
DR   EMBL; AL662889; CAH71866.1; JOINED; Genomic_DNA.
DR   EMBL; AL591721; CAH71867.1; -; Genomic_DNA.
DR   EMBL; AC096539; CAH71867.1; JOINED; Genomic_DNA.
DR   EMBL; AL592151; CAH71867.1; JOINED; Genomic_DNA.
DR   EMBL; AL662889; CAH71867.1; JOINED; Genomic_DNA.
DR   EMBL; AL592151; CAH72891.1; -; Genomic_DNA.
DR   EMBL; AC096539; CAH72891.1; JOINED; Genomic_DNA.
DR   EMBL; AL591721; CAH72891.1; JOINED; Genomic_DNA.
DR   EMBL; AL662889; CAH72891.1; JOINED; Genomic_DNA.
DR   EMBL; AL592151; CAH72892.1; -; Genomic_DNA.
DR   EMBL; AC096539; CAH72892.1; JOINED; Genomic_DNA.
DR   EMBL; AL591721; CAH72892.1; JOINED; Genomic_DNA.
DR   EMBL; AL662889; CAH72892.1; JOINED; Genomic_DNA.
DR   EMBL; AL662889; CAH73072.1; -; Genomic_DNA.
DR   EMBL; AC096539; CAH73072.1; JOINED; Genomic_DNA.
DR   EMBL; AL591721; CAH73072.1; JOINED; Genomic_DNA.
DR   EMBL; AL592151; CAH73072.1; JOINED; Genomic_DNA.
DR   EMBL; AL662889; CAH73073.1; -; Genomic_DNA.
DR   EMBL; AC096539; CAH73073.1; JOINED; Genomic_DNA.
DR   EMBL; AL591721; CAH73073.1; JOINED; Genomic_DNA.
DR   EMBL; AL592151; CAH73073.1; JOINED; Genomic_DNA.
DR   EMBL; CH471148; EAW77093.1; -; Genomic_DNA.
DR   EMBL; CH471148; EAW77094.1; -; Genomic_DNA.
DR   EMBL; BC121154; AAI21155.1; -; mRNA.
DR   CCDS; CCDS31076.1; -. [Q9Y243-2]
DR   CCDS; CCDS31077.1; -. [Q9Y243-1]
DR   PIR; A59380; A59380.
DR   PIR; T17287; T17287.
DR   RefSeq; NP_001193658.1; NM_001206729.1. [Q9Y243-2]
DR   RefSeq; NP_005456.1; NM_005465.4. [Q9Y243-1]
DR   RefSeq; NP_859029.1; NM_181690.2. [Q9Y243-2]
DR   RefSeq; XP_005273051.1; XM_005272994.4. [Q9Y243-1]
DR   RefSeq; XP_005273052.1; XM_005272995.2. [Q9Y243-1]
DR   UniGene; Hs.498292; -.
DR   PDB; 2X18; X-ray; 1.46 A; A/B/C/D/E/F/G/H=1-118.
DR   PDBsum; 2X18; -.
DR   ProteinModelPortal; Q9Y243; -.
DR   SMR; Q9Y243; -.
DR   BioGrid; 115318; 26.
DR   DIP; DIP-32584N; -.
DR   IntAct; Q9Y243; 7.
DR   MINT; MINT-222821; -.
DR   STRING; 9606.ENSP00000263826; -.
DR   BindingDB; Q9Y243; -.
DR   ChEMBL; CHEMBL4816; -.
DR   GuidetoPHARMACOLOGY; 2286; -.
DR   iPTMnet; Q9Y243; -.
DR   PhosphoSitePlus; Q9Y243; -.
DR   BioMuta; AKT3; -.
DR   DMDM; 12643943; -.
DR   PaxDb; Q9Y243; -.
DR   PeptideAtlas; Q9Y243; -.
DR   PRIDE; Q9Y243; -.
DR   DNASU; 10000; -.
DR   Ensembl; ENST00000263826; ENSP00000263826; ENSG00000117020. [Q9Y243-1]
DR   Ensembl; ENST00000336199; ENSP00000336943; ENSG00000117020. [Q9Y243-2]
DR   Ensembl; ENST00000366539; ENSP00000355497; ENSG00000117020. [Q9Y243-1]
DR   Ensembl; ENST00000366540; ENSP00000355498; ENSG00000117020. [Q9Y243-2]
DR   Ensembl; ENST00000613395; ENSP00000479922; ENSG00000275199. [Q9Y243-2]
DR   Ensembl; ENST00000619536; ENSP00000483054; ENSG00000275199. [Q9Y243-2]
DR   Ensembl; ENST00000621586; ENSP00000479081; ENSG00000275199. [Q9Y243-1]
DR   GeneID; 10000; -.
DR   KEGG; hsa:10000; -.
DR   UCSC; uc001hzz.2; human. [Q9Y243-1]
DR   CTD; 10000; -.
DR   DisGeNET; 10000; -.
DR   GeneCards; AKT3; -.
DR   HGNC; HGNC:393; AKT3.
DR   HPA; CAB013090; -.
DR   HPA; HPA026441; -.
DR   MalaCards; AKT3; -.
DR   MIM; 611223; gene.
DR   MIM; 615937; phenotype.
DR   neXtProt; NX_Q9Y243; -.
DR   OpenTargets; ENSG00000117020; -.
DR   Orphanet; 99802; Hemimegalencephaly.
DR   Orphanet; 83473; Megalencephaly - polymicrogyria - postaxial polydactyly - hydrocephalus.
DR   PharmGKB; PA24686; -.
DR   eggNOG; KOG0598; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00860000133668; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; Q9Y243; -.
DR   KO; K04456; -.
DR   OMA; REYIKNW; -.
DR   OrthoDB; EOG091G06FF; -.
DR   PhylomeDB; Q9Y243; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs.
DR   SABIO-RK; Q9Y243; -.
DR   SignaLink; Q9Y243; -.
DR   SIGNOR; Q9Y243; -.
DR   ChiTaRS; AKT3; human.
DR   GeneWiki; AKT3; -.
DR   GenomeRNAi; 10000; -.
DR   PRO; PR:Q9Y243; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000117020; -.
DR   CleanEx; HS_AKT3; -.
DR   ExpressionAtlas; Q9Y243; baseline and differential.
DR   Genevisible; Q9Y243; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005622; C:intracellular; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048854; P:brain morphogenesis; IEA:Ensembl.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0000002; P:mitochondrial genome maintenance; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; IMP:UniProtKB.
DR   CDD; cd05593; STKc_PKB_gamma; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR034675; Akt3.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Disease mutation; Disulfide bond;
KW   Glycoprotein; Kinase; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    479       RAC-gamma serine/threonine-protein
FT                                kinase.
FT                                /FTId=PRO_0000085611.
FT   DOMAIN        5    107       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      148    405       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      406    479       AGC-kinase C-terminal.
FT   NP_BIND     154    162       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    271    271       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     177    177       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     305    305       Phosphothreonine; by PDPK1.
FT                                {ECO:0000269|PubMed:9512493}.
FT   MOD_RES     447    447       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     472    472       Phosphoserine; by PKC/PRKCZ.
FT                                {ECO:0000269|PubMed:12162751}.
FT   CARBOHYD    302    302       O-linked (GlcNAc) threonine.
FT                                {ECO:0000250}.
FT   CARBOHYD    309    309       O-linked (GlcNAc) threonine.
FT                                {ECO:0000250}.
FT   DISULFID     59     76       {ECO:0000250}.
FT   DISULFID    293    307       {ECO:0000250}.
FT   VAR_SEQ     452    479       YDEDGMDCMDNERRPHFPQFSYSASGRE -> CQQSDCGML
FT                                GNWKK (in isoform 2).
FT                                {ECO:0000303|PubMed:11230166,
FT                                ECO:0000303|PubMed:11387345,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_004947.
FT   VARIANT      17     17       E -> K (in MPPH2 and melanoma; results in
FT                                activation of AKT; dbSNP:rs397514606).
FT                                {ECO:0000269|PubMed:18813315,
FT                                ECO:0000269|PubMed:22500628,
FT                                ECO:0000269|PubMed:22729223}.
FT                                /FTId=VAR_065830.
FT   VARIANT     171    171       G -> R (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040358.
FT   VARIANT     229    229       N -> S (in MPPH2; dbSNP:rs397514605).
FT                                {ECO:0000269|PubMed:22729224,
FT                                ECO:0000269|PubMed:23745724}.
FT                                /FTId=VAR_069260.
FT   VARIANT     465    465       R -> W (in MPPH2; disease phenotype
FT                                overlaps with megalencephaly-capillary
FT                                malformation syndrome;
FT                                dbSNP:rs587776935).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069261.
FT   MUTAGEN     305    305       T->A: No activation after pervanadate
FT                                treatment. {ECO:0000269|PubMed:11387345}.
FT   MUTAGEN     305    305       T->D: 2-fold increase of phosphorylation
FT                                steady state level, no activation after
FT                                pervanadate treatment.
FT                                {ECO:0000269|PubMed:11387345}.
FT   MUTAGEN     447    447       T->A: No effect.
FT                                {ECO:0000269|PubMed:11387345}.
FT   MUTAGEN     447    447       T->D: No effect.
FT                                {ECO:0000269|PubMed:11387345}.
FT   MUTAGEN     472    472       S->A: 67% decrease of activity after
FT                                pervanadate treatment.
FT                                {ECO:0000269|PubMed:10092583}.
FT   MUTAGEN     472    472       S->D: 1.4-fold increase of
FT                                phosphorylation steady state level, 50%
FT                                decrease of activity after pervanadate
FT                                treatment. {ECO:0000269|PubMed:10092583}.
FT   CONFLICT    279    279       L -> R (in Ref. 9; AAI21155).
FT                                {ECO:0000305}.
FT   STRAND        6     15       {ECO:0000244|PDB:2X18}.
FT   STRAND       17     30       {ECO:0000244|PDB:2X18}.
FT   STRAND       33     41       {ECO:0000244|PDB:2X18}.
FT   HELIX        44     46       {ECO:0000244|PDB:2X18}.
FT   STRAND       51     55       {ECO:0000244|PDB:2X18}.
FT   STRAND       60     64       {ECO:0000244|PDB:2X18}.
FT   STRAND       66     68       {ECO:0000244|PDB:2X18}.
FT   STRAND       71     75       {ECO:0000244|PDB:2X18}.
FT   TURN         80     82       {ECO:0000244|PDB:2X18}.
FT   STRAND       84     88       {ECO:0000244|PDB:2X18}.
FT   HELIX        92    113       {ECO:0000244|PDB:2X18}.
SQ   SEQUENCE   479 AA;  55775 MW;  F08BDDE6502E78FB CRC64;
     MSDVTIVKEG WVQKRGEYIK NWRPRYFLLK TDGSFIGYKE KPQDVDLPYP LNNFSVAKCQ
     LMKTERPKPN TFIIRCLQWT TVIERTFHVD TPEEREEWTE AIQAVADRLQ RQEEERMNCS
     PTSQIDNIGE EEMDASTTHH KRKTMNDFDY LKLLGKGTFG KVILVREKAS GKYYAMKILK
     KEVIIAKDEV AHTLTESRVL KNTRHPFLTS LKYSFQTKDR LCFVMEYVNG GELFFHLSRE
     RVFSEDRTRF YGAEIVSALD YLHSGKIVYR DLKLENLMLD KDGHIKITDF GLCKEGITDA
     ATMKTFCGTP EYLAPEVLED NDYGRAVDWW GLGVVMYEMM CGRLPFYNQD HEKLFELILM
     EDIKFPRTLS SDAKSLLSGL LIKDPNKRLG GGPDDAKEIM RHSFFSGVNW QDVYDKKLVP
     PFKPQVTSET DTRYFDEEFT AQTITITPPE KYDEDGMDCM DNERRPHFPQ FSYSASGRE
//
